You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《復牌公告》中國醫療集團(08225.HK)向藥監局申請恢復利托那韋生產
阿思達克 01-30 08:12

中國醫療集團(08225.HK)公布,旗下新型冠狀病毒肺炎臨床特別專案組研究發現利托那韋(Ritonavir)對新型冠狀病毒(2019-nCoV)有抑制作用和療效報告,中國科學院武漢病毒研究所等也發現其在細胞層面上對新型冠狀病毒(2019-nCoV)有較好抑制作用。

目前集團關聯公司萬全萬特廈門有限公司是一家唯一國內歷史生產過該產品製劑,企業同時擁有原料批文,申請相關專利和已經向國家藥監局申請重新恢復生產。集團將負責進一步臨床研究和申報工作。

集團疫情臨床特別行動組組還在繼續晝夜從上千個可能治療的新老藥品中通過臨床大數據進行篩選。

公司董事局注意到昨日(29日)股份之成交價及成交量異常變動。經合理查詢後,董事局確認並不知悉導致價格或成交量變動的任何原因,或任何必須公告以避免公司證券出現虛假市場的資料,或須予披露的任何內幕消息。

該公司已申請股份於今早起復牌。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account